Nuvalent
NASDAQ · NUVL·Cambridge, MA·Mid-cap·Phase 3
Clinical-stage precision oncology biotech designing selective kinase inhibitors for kinase-driven cancers. Lead programs: zidesamtinib (parent-selective ROS1) in NSCLC, neladalkib (ALK-selective) in NSCLC, both with pivotal Phase 3 trials underway.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Nuvalent Corporate Overview April 2026 | Corporate overview | April 28, 2026 | 60 |